Mendes, Augusto J.
Ribaldi, Federica
Lathuiliere, Aurelien
Ashton, Nicholas J.
Zetterberg, Henrik
Abramowicz, Marc
Scheffler, Max
Assal, Frédéric
Garibotto, Valentina
Blennow, Kaj
Frisoni, Giovanni B.
Funding for this research was provided by:
University of Geneva
Article History
Received: 5 February 2024
Accepted: 7 May 2024
First Online: 16 May 2024
Declarations
:
: The study was approved by Geneva Ethics Committee (PB_2016 − 01346 and 2020_00403). All participants signed an informed consent form prior to enrollment in the study.
: All authors consent to the publication of this study.
: All authors had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
: GBF has received unrestricted grants and support for event organisation from ROCHE Pharmaceuticals; OM Pharma; EISAI Pharmaceuticals; Biogen Pharmaceuticals. VG received grants and speaker fees through her institution from Siemens Healthineers, GE Healthcare, Novo Nordisk and Janssen. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). The other authors have nothing to disclose.